CoChat

Vasopressin in chronic kidney disease: an elephant in the room?

Open access
Torres, Vicente E. · 2009 · Kidney International
Cited by 58

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

Abstract

The report by Perico et al that a dual arginine vasopressin (AVP) V2 and V1a receptor antagonist lowers blood pressure, proteinuria and glomerulosclerosis in 5/6 nephrectomized rats points to a potential therapeutic value of AVP receptor antagonists in the treatment of chronic kidney disease (CKD). A large body of evidence suggests that AVP likely contributes to CKD progression by its V2 and V1a-mediated effects on renal hemodynamics, blood pressure, and mesangial and/or epithelial cells. The relative contribution of V2 and V1a receptors to CKD progression and potential usefulness of V2 and V1a receptor antagonists for its treatment are not well defined.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/ki.2009.325

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 4 references

Cited by

See all 58

Metadata

Authors
Torres, V. E.
Venue
Kidney International
Publisher
Elsevier BV
Published
2009-11
Volume
76
Issue
9
Pages
925-928
ISSN
0085-2538 (ISSN-L)
OpenAlex
W2001771261
Cited by
58
References
4
FWCI
1.03
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Vasopressin in chronic kidney disease: an elephant in the room? https://app.cochat.ai/papers/10.1038/ki.2009.325
The paper
Torres, V. E. (2009). Vasopressin in chronic kidney disease: an elephant in the room? Kidney International. https://doi.org/10.1038/ki.2009.325

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.